Orexo: One Of The Best Ever Quarters
Edison | Jul 15, 2018 04:45AM ET
In a well-received set of quarterly results, Orexo AB ADR (OTC:ORXOY) continued to execute on Zubsolv in the US, which, for the second quarter running, continued to be the only branded product in the category that increased its market share in the face of multiple generics. Zubsolv US revenues of SEK158.4m grew by 27.6% y-o-y, driving total revenues to SEK200m. EBITDA of SEK50.6m, cash flow from operations of SEK39m and a gross cash balance of SEK494.8m made Q218 one of Orexo’s best ever quarters.
Zubsolv keeps on gaining market share
As Orexo’s biggest product, Zubsolv’s US sales largely dictate Orexo’s quarterly performance and Q218 was a knock-out quarter for Zubsolv. Total net revenues were SEK199.7m up 25.5% y-o-y and driven by Zubsolv US revenues of SEK158.4m (up 27.6% y-o-y in SEK terms, or 29.8% in local currencies) including a $1.4m prior period revenue adjustment. We had already included the €3m milestone from Mundipharma for the EU launch of Zubsolv (royalties have not yet been recorded for the last quarter) in our model, but this, in addition to a further quarter of cash generation, resulted in a gross cash balance of SEK494.8m (SEK294.3m at end H117). Orexo’s minor product royalty streams did not materially affect its profitability, although the SEK11.9m from Abstral was nearly double our quarterly estimate of SEK6.1m.
To read the entire report Please click on the pdf File Below:
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.